Device for Promoting Survival of Congested Tissue Flaps

促进充血组织瓣存活的装置

基本信息

  • 批准号:
    7858344
  • 负责人:
  • 金额:
    $ 63.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-04-15 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The use of microsurgical procedures is increasing, and includes free tissue transfers and/or reconstruction after cancer resection, limb transplantation, breast reconstruction, and traumatic amputation, avulsion, or gunshot injury. Venous congestion is a serious complication of these types of procedures. Replanted tissues can become severely congested, and if uncorrected, tissue death results. Currently, live leeches are used to treat this condition, but are psychologically traumatic to patients, and are often ineffective in preventing tissue death. In SBIR Phase I and II projects, SpectroCon developed new technology for the treatment of venous congestion. AutoFlow is a fully automated medical device. In an animal model, AutoFlow removed excess blood, promoted blood flow in congested tissues, safely contained removed blood, and demonstrated autotransfusion capability. NHLBI supports Competing Continuation Awards of SBIR Phase II grants to improve devices and conduct clinical studies toward approval by a Federal regulatory agency. Accordingly, our overall goals for the Phase II Continuation period are to: (1) Complete regulatory compliance activities with the Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) and toward device approval via a Premarket Approval (PMA) application, and (2) Complete a clinical trial in human patients in which AutoFlow is compared with the standard of care for treatment of venous congestion (i.e. use of medicinal leeches). Our specific aims are: (1) To ensure compliance with regulatory standards toward the goal of achieving FDA approval of an IDE, and further approval to market AutoFlow via the PMA mechanism; (2) To determine the safety of using AutoFlow in human patients with venous congestion, and (3) To determine efficacy of using AutoFlow in human patients with venous congestion. These aims are critical for gaining market approval from the FDA for AutoFlow therapy and in establishing the safety and efficacy of AutoFlow, in comparison with medicinal leeches. Achieving these aims will create a large functional divide between use of AutoFlow and medicinal leeches, and will establish AutoFlow as the universally preferred method for the treatment for venous congestion in the marketplace.Project Narrative Because live leeches are less than optimal for treating venous congestion, new technology is needed that will treat this condition more effectively. SpectroCon has developed AutoFlow, a fully automated medical device, because it will be beneficial in restoring function to persons experiencing complications in breast reconstruction, head and neck cancer surgery, and trauma surgery. Effective salvage of amputated limbs, fingers, breasts, or critical tissues of the head and neck will clearly enhance physical, occupational, and vocational rehabilitative potential, as well as speech, swallowing, general appearance, and quality of life.
描述(由申请人提供):显微外科手术的使用正在增加,包括癌症切除术后的游离组织移植和/或重建、肢体移植、乳房重建和创伤性截肢、撕脱或枪伤。静脉充血是这类手术的严重并发症。移植的组织可能会严重充血,如果不及时纠正,会导致组织死亡。目前,活水蛭被用来治疗这种情况,但对患者造成心理创伤,并且通常在防止组织死亡方面无效。在SBIR I和II期项目中,SpectroCon开发了治疗静脉充血的新技术。AutoFlow是一种全自动医疗器械。在动物模型中,AutoFlow清除了多余的血液,促进了充血组织中的血流,安全地容纳了清除的血液,并证明了自体输血能力。NHLBI支持SBIR第二阶段赠款的竞争继续奖,以改进设备并进行临床研究,以获得联邦监管机构的批准。因此,我们在第二阶段延续期的总体目标是:(1)完成与美国食品药品监督管理局(FDA)的监管合规活动,以获得试验用器械豁免(IDE),并通过上市前批准(PMA)申请获得器械批准,和(2)完成人类患者的临床试验,其中AutoFlow与治疗静脉充血的护理标准进行比较(即使用医用水蛭)。我们的具体目标是:(1)确保符合监管标准,以实现FDA批准IDE的目标,并通过PMA机制进一步批准AutoFlow上市;(2)确定在静脉充血患者中使用AutoFlow的安全性,以及(3)确定在静脉充血患者中使用AutoFlow的有效性。这些目标对于获得FDA对AutoFlow治疗的市场批准以及确定AutoFlow与药用水蛭相比的安全性和有效性至关重要。这些目标的实现将在AutoFlow和医用水蛭的使用之间产生巨大的功能差异,并将AutoFlow确立为市场上治疗静脉充血的普遍首选方法。项目叙述由于活体水蛭在治疗静脉充血方面并不理想,因此需要新的技术来更有效地治疗这种情况。SpectroCon开发了AutoFlow,一种全自动医疗设备,因为它将有利于恢复乳房重建,头颈癌手术和创伤手术并发症患者的功能。对截肢、手指、乳房或头颈部重要组织的有效挽救将明显提高身体、职业和职业康复潜力,以及言语、吞咽、一般外观和生活质量。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN A. RUSSELL其他文献

JOHN A. RUSSELL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN A. RUSSELL', 18)}}的其他基金

Device for Promoting Survival of Congested Tissue Flaps
促进充血组织瓣存活的装置
  • 批准号:
    7393897
  • 财政年份:
    2008
  • 资助金额:
    $ 63.91万
  • 项目类别:
Device for Promoting Survival of Congested Tissue Flaps
促进充血组织瓣存活的装置
  • 批准号:
    7614210
  • 财政年份:
    2008
  • 资助金额:
    $ 63.91万
  • 项目类别:
Device for Promoting Survival of Congested Tissue Flaps
促进充血组织瓣存活的装置
  • 批准号:
    6874494
  • 财政年份:
    2002
  • 资助金额:
    $ 63.91万
  • 项目类别:
Device for Promoting Survival of Congested Tissue Flaps
促进充血组织瓣存活的装置
  • 批准号:
    6785787
  • 财政年份:
    2002
  • 资助金额:
    $ 63.91万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 63.91万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 63.91万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 63.91万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 63.91万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 63.91万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 63.91万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 63.91万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 63.91万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 63.91万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 63.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了